Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    New press releases were added to the page, highlighting trial updates, regulatory recommendations, and 2026 results for multiple programs. Several older releases were removed to keep the archive current.
    Difference
    5%
    Check dated 2026-07-28T05:43:42.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A new press release item dated 14 July 2026 announces an exclusive global license for the EGFR inhibitor Zegfrovy with Dizal Pharmaceutical. The EMERALD-3 trial result press release from 01 June 2026 has been removed.
    Difference
    0.9%
    Check dated 2026-07-20T22:25:53.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A new press release entry dated 09 July 2026 about the CARDIO-TTRansform trial has been added, and the 29 May 2026 CARES Phase III update has been removed from the archive.
    Difference
    0.9%
    Check dated 2026-07-13T21:00:20.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page adds new June 2026 press releases (Enhertu EU approval, Efzimfotase alfa trial results, Datroway CHMP recommendation) and removes older US approvals (Imfinzi, Datroway), aligning the listing with current company news.
    Difference
    5%
    Check dated 2026-06-29T10:55:18.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    A new press release entry dated 15 June 2026 about Ultomiris being granted Priority Review in the US for immunoglobulin A nephropathy was added to the press releases. The 22 May 2026 entry about Enhertu being recommended for EU approval by CHMP was removed from the list.
    Difference
    0.9%
    Check dated 2026-06-22T05:25:16.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    Two new press releases were added: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (12 June 2026) and Elecoglipron moves to Phase III programme (08 June 2026). Several previously listed items were removed from the press releases listing, including Camizestrant in combination with a CDK4/6 inhibitor recommended for EU approval, the ASCO 2026 data showcase note, and an email entry (22 May 2026).
    Difference
    5%
    Check dated 2026-06-15T05:33:50.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.